Clinical trial · Observational
Patients' Preferences for Adjuvant Endocrine Therapy in Early Breast Cancer
Evaluation of Endocrine Therapy and Patients Preferences in Early Breast Cancer - Patients' Preferences for Adjuvant Endocrine Therapy in Early Breast Cancer.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Preference studies reveal how individuals trade-off the potential benefits, harms and inconveniences of a treatment by determining the minimum benefits they judge sufficient to make the treatment worthwhile. They are especially relevant to adjuvant therapies where individuals must weigh up modest survival benefits only realized in time by no recurrence of their cancer with side effects predominantly experienced whilst on the treatment. Previously it was reported, for example, that over 50% of women who had adjuvant chemotherapy for early breast cancer judged a 1% improvement in 5 year survival rates sufficient to make it worthwhile. Larger survival benefits were required for longer duration adjuvant hormonal therapy where over 50% of women required at least 5% improvement in 5 year survival rates to make it worthwhile.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Endocrine Breast Diseases | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Completion of questionnaires | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Group 1 - before starting ET
- description
- women candidate to receive ET and interviewed before starting treatment
- interventionNames
- Other: Completion of questionnaires
- label
- Group 2 - within 1 year of ET
- description
- women interviewed within 1 years from beginning of ET
- interventionNames
- Other: Completion of questionnaires
- label
- Group 3 - between 4 and 6 years of ET
- description
- women interviewed after more than 4 years but no more than 6 years of ET
- interventionNames
- Other: Completion of questionnaires
Primary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Women candidate to adjuvant hormonal therapy for breast cancer before the start of therapy * Women who are receiving hormonal therapy (within 1 year from beginning) * Women who are receiving hormonal therapy (who had receive at least 4 or 5 or 6 years of hormonal therapy) * Patients who underwent to radical surgery for breast cancer * Patients who have received neoadjuvant or adjuvant chemotherapy are also eligible * Hormonal receptors positive breast cancer (ER and or PgR \>1%) * Sufficient literacy in Italian to complete the questionnaires. Exclusion Criteria: * Patients who had received at least 1 year and no more than 3 years of hormonal therapy * Patients who are receiving hormonal therapy (who had receive 7 years or more of hormonal therapy)
References
Publications (0)
Data not yet available